Riskpilot← Back to searchSign inGet full accessSPECIALLÆGE INGE STENDEVAD NIELSEN ApS
APSActiveCVR 12601530Nordre Strandvej 7Medical specialists activities · NACE 8622Est. 19889 employees
Revenue 2025
DKK 3,9M
+2% vs 2024
EBITDA margin
52.2%
0% vs 2024
Equity ratio
92.7%
Financial strength
Net profit 2025
DKK 1,6M
-4% vs 2024
| Revenue | DKK 3,9M | +2% |
| EBITDA | DKK 2M | +0% |
| Net profit | DKK 1,6M | -4% |
| Total assets | DKK 10,6M | +1% |
| Equity | DKK 9,8M | +2% |
| Employees | 9 | — |
Legal name
SPECIALLÆGE INGE STENDEVAD NIELSEN ApS
CVR number
12601530
Legal form
Anpartsselskab
NACE code
8622 · Medical specialists activities
Founded
1. december 1988
Share capital
DKK 200.000
Employees
9 (FTE)
VAT registered
No
Audit selected
Yes
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør
Company purpose
Selskabets formål er at drive speciallægevirksomhed og virksomhed, der naturligt er forbunden hermed.
Address
Nordre Strandvej 7
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 4.121 | 3.930 | 3.862 | 3.829 | 3.893 |
| Staff expenses | -1.909 | -1.806 | -1.814 | -1.804 | -1.860 |
| EBITDA | 2.212 | 2.124 | 2.049 | 2.025 | 2.033 |
| Depreciation & amort. | -138 | -149 | -141 | -104 | -106 |
| EBIT | 2.073 | 1.975 | 1.907 | 1.921 | 1.926 |
| Net financials | 86 | 132 | 128 | 286 | 187 |
| Profit before tax | 2.159 | 2.107 | 2.035 | 2.207 | 2.114 |
| Tax | 468 | 474 | 448 | 486 | 465 |
| Net profit | 1.692 | 1.633 | 1.587 | 1.720 | 1.649 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 8.344 | 9.343 | 10.641 | 10.425 | 10.562 |
| Equity | 7.107 | 8.540 | 9.927 | 9.647 | 9.796 |
| Long-term debt | 29 | 31 | 31 | 0 | 0 |
| Short-term debt | 1.208 | 771 | 683 | 778 | 767 |
| Total debt | 1.237 | 802 | 714 | 778 | 767 |
EBITDA margin
52.2%
This company
15.8%
Market median
+230% vs market
20212025
Equity ratio
92.7%
This company
38.2%
Market median
+143% vs market
20212025
Return on equity
16.8%
This company
18.4%
Market median
+9% vs market
20212025
Net profit margin
42.4%
This company
8.1%
Market median
+423% vs market
20212025
Asset turnover
0.37×
This company
1.12×
Market median
-67% vs market
20212025
Debt / equity
0.08×
This company
0.62×
Market median
+87% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
IS Management | Management | 1988 |
HC Founder | Founder | 1988 |
KJ Founder | Founder | 1988 |
| Former (3) | ||
JV Audit | Audit | 1988 – 1998 |
MC | Audit | 1988 – 2017 |
MS Management | Management | 1988 – 1994 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Speciallægeholdingselskabet Inge Stendevad Nielsen ApS
SPECIALLÆGE INGE STENDEVAD NIELSEN ApS (this company)Board members of SPECIALLÆGE INGE STENDEVAD NIELSEN ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Inge Stendevad Nielsen | Management | 0 companies |
| Jens Vindfeldt | Audit | 0 companies |
| Mogens Christian Hald | Audit | 0 companies |
| Morten Støwer Christensen | Management | 0 companies |
| Henning Christensen | Founder | 0 companies |
| Klaus Jørgen Machold Blach | Founder | 0 companies |